TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.30) per share which missed the analyst consensus estimate of $(0.27) by 11.11 percent. This is a 42.86 percent decrease over losses of $(0.21) per share from the same period last year. The company reported quarterly sales of $665.00 thousand which missed the analyst consensus estimate of $1.35 million by 50.74 percent. This is a 90.78 percent decrease over sales of $7.21 million the same period last year.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。